Yadav R, El Kossi M, Belal D, Sharma A, Halawa A. Post-transplant malignancy: Focusing on virus-associated etiologies, pathogenesis, evidence-based management algorithms, present status of adoptive immunotherapy and future directions. World J Meta-Anal 2023; 11(7): 317-339 [DOI: 10.13105/wjma.v11.i7.317]
Corresponding Author of This Article
Rahul Yadav, MBBS, MCh, MS, Chief Doctor, Director, Department of Urology, Kidney Transplant and Robotic Uro-oncology, Tender Palm Super Speciality Hospital, Amar Shaheed Path, Sector 7, Gomti Nagar Extension, Lucknow 226010, Uttar Pradesh, India. rahulyadavdr@gmail.com
Research Domain of This Article
Transplantation
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Meta-Anal. Dec 18, 2023; 11(7): 317-339 Published online Dec 18, 2023. doi: 10.13105/wjma.v11.i7.317
Post-transplant malignancy: Focusing on virus-associated etiologies, pathogenesis, evidence-based management algorithms, present status of adoptive immunotherapy and future directions
Rahul Yadav, Mohsen El Kossi, Dawlat Belal, Ajay Sharma, Ahmed Halawa
Rahul Yadav, Department of Urology, Kidney Transplant and Robotic Uro-oncology, Tender Palm Super Speciality Hospital, Lucknow 226010, Uttar Pradesh, India
Rahul Yadav, Department of Urology and Kidney Transplant, Charak Hospital and Research Centre, Lucknow 226003, Uttar Pradesh, India
Mohsen El Kossi, Department of Nephrology, Doncaster Royal Infirmary, Doncaster DN2 5LT, United Kingdom
Dawlat Belal, Department of Nephrology and Medicine, Kasr El-Ainy School of Medicine, Cairo University, Cairo 11562, Egypt
Ajay Sharma, Department of Transplant Surgery, Royal Liverpool University Hospitals, Liverpool L7 8XP, United Kingdom
Ahmed Halawa, Department of Transplantation, Sheffield Teaching Hospitals, Sheffield S57AU, United Kingdom
Author contributions: Yadav R performed research, wrote the paper; El Kossi M and Belal D, reviewed and edited the manuscript; Sharma A and Halawa A, conceptualized the study, reviewed, and edited the manuscript.
Conflict-of-interest statement: Authors declare no conflict of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Rahul Yadav, MBBS, MCh, MS, Chief Doctor, Director, Department of Urology, Kidney Transplant and Robotic Uro-oncology, Tender Palm Super Speciality Hospital, Amar Shaheed Path, Sector 7, Gomti Nagar Extension, Lucknow 226010, Uttar Pradesh, India. rahulyadavdr@gmail.com
Received: May 18, 2023 Peer-review started: May 18, 2023 First decision: July 28, 2023 Revised: August 23, 2023 Accepted: October 8, 2023 Article in press: October 8, 2023 Published online: December 18, 2023 Processing time: 210 Days and 3.7 Hours
Core Tip
Core Tip: Post-transplant malignancy poses a serious threat with increased risk in organ recipients, varying with the intensity of net immunosuppression. Various virus infections are either causative or associative or promote the development of post-transplant malignancies. It is crucial to be aware of different viral infections so as to pre-emptively screen viral infections and survey for post-transplant cancers, helping early diagnosis, thereby favoring improved outcomes and graft survival. Transplant clinicians must be up to date on current management strategies with the vital role of immunosuppression reduction and options like antivirals, rituximab, chemotherapy, adoptive immunotherapy, topical therapy and surgery based on individual case characteristics.
